Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 7/20 | 0.37 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29501726 | 1.00 | HTR1A (0.38) | HTR1AADRA1DADRA1BADRA1AKCNA3 | |
| SCHEMBL29501779 | 0.92 | KCNA3 (0.31) | HTR1AADRA1DADRA1BADRA1AKCNA3 | |
| SCHEMBL23672521 | 0.92 | KCNA3 (0.31) | HTR1AADRA1DADRA1BADRA1AKCNA3 | |
| SCHEMBL23672523 | 0.92 | KCNA3 (0.31) | HTR1AADRA1DADRA1BADRA1AKCNA3 | |
| SCHEMBL23680928 | 0.91 | TP53 (0.34) | HTR1AADRA1DADRA1BADRA1AATM | |
| SCHEMBL29501780 | 0.91 | TP53 (0.34) | HTR1AADRA1DADRA1BADRA1AATM | |
| SCHEMBL23680929 | 0.91 | MET (0.33) | HTR1AADRA1DADRA1BADRA1AKCNA3 | |
| SCHEMBL29501723 | 0.91 | MET (0.33) | HTR1AADRA1DADRA1BADRA1AKCNA3 | |
| SCHEMBL23680932 | 0.90 | MEN1 (0.37) | — | |
| SCHEMBL23680945 | 0.90 | EGFR (0.34) | HTR1AADRA1DADRA1BADRA1AKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210227826-A1 | Microbiocidal Picolinamide Derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210227826-A1 | Microbiocidal Picolinamide Derivatives | CASP2, CASP1, MSR1 | HTR1A 1944/4885ADRA1D 3264/4885ADRA1B 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.